The industrial laser firm's strategic pivot into the electronic warfare and operational resilience markets is fueled by a new capital raise and key acquisitions.
The $0.3 million deal with a major Southern European telecom carrier boosts the network solutions provider's shares in after-hours trading.
Company transfers equity stake in a strategic deal for future capital rights, resolving outstanding brand disputes and boosting investor confidence.
The biotech company's shares surged after announcing an ambitious plan for its sublingual drug delivery technology and boosting its 2026 financial outlook.
The non-dilutive capital is aimed at advancing the company's battery manufacturing capabilities and bolstering its position in the U.S. supply chain.
The approval covers a first-line maintenance treatment for an aggressive form of small cell lung cancer, a historically difficult-to-treat disease.
Autonomous trucking firm's shares rose 2.2% in after-hours trading after the billionaire's fund disclosed a 5.7% passive investment.
The regulator's green light for Rhapsido, a first-in-class oral treatment for chronic hives, positions the company to challenge injectable rivals.